Daniela Couto

Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies.

NewAmsterdam Pharma BV develops novel drugs to treat dyslipidemia. It operates as a biotechnology company and develops anti-dyslipidemic compounds in cardiovascular disease indications. The firm's product DEZ-001 develops a potent cholesteryl ester transfer protein inhibitor that has shown a decrease of low-density lipoprotein levels, and an increase of high-density lipoprotein levels. The company was founded by John J. P. Kastelein in 2012 and is headquartered in Naarden, the Netherlands.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

SurgVision BV provides optical imaging camera systems. It develops integrated optical imaging platforms, including camera, software and target specific tracer, for specific disease areas like breast cancer surgery. The company was founded by Vasilis Ntziachristos and Ton van den Hoven in 2011 and is headquartered in 't Harde, the Netherlands.

VarmX BV is a spin-off from Leiden University Medical Center (LUMC) founded in 2016 by Professor Pieter Reitsma, a world-leading expert in hemostasis and thrombosis. VarmX is based in Leiden, NL. The Dutch company's lead compound, VMX-C001, is a modified recombinant blood factor X developed for the treatment of severe spontaneous bleeding and for the prevention of bleeding during urgent surgery in patients taking oral factor Xa inhibitors (FXa DOACs) as anticoagulation therapy. The company is supported by a strong syndicate of investors. Jan K. Öhrström has been the CEO of the company since 2018.

Cristal Delivery BV develops and manufactures nanomedicines for therapeutic drug optimization. It offers pipeline, oncology, and inflammation programs. The company was founded by Joost J. M. Holthuis and Cristianne Rijcken in April 2011 and is headquartered in Maastricht, the Netherlands.

Dualyx NV is a biotech company based in Ghent, Belgium that focuses on developing novel Treg-based therapies for patients with difficult-to-treat autoimmune diseases. The CEO of the company is Wouter Verhoeven, and it is located in Zwijnaarde, Belgium. Dualyx has developed a pipeline of highly promising immune modulating programs, including DT-001, an antibody agonist program targeting the TNF receptor 2 (TNFR2), which is currently in IND-enabling studies. The Belgian company aims to create next-generation biologic drugs for autoimmunity therapies with novel mechanisms of action, lower toxicity, and improved patient outcomes than traditional therapeutics. The company was founded in 2020 by Luc van Rompaey in collaboration with Wurzburg University, Argenx, VIB, Ghent University, and KU Leuven.

Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands.

InnoCore Technologies BV develops drug delivery technologies. It serves the pharmaceutical and medical device industry by developing and manufacturing innovative drug delivery systems that enhance their products. The company was founded by Theodorus Adrianus Cornelius Flipsen and Rob Steendam in 2004 and is headquartered in Groningen, the Netherlands.

Accenture LLC operates as a global management consulting, technology services and outsourcing company. The company is headquartered in Reston, VA.

EMD Serono, Inc. operates as a biopharmaceutical firm. The firm develops recombinant prescription medicines. Its therapies include neurology and immunology, metabolic endocrinology, fertility, and oncology. The company was founded in 1971 and is headquartered in Rockland, MA.

Metronet (UK) Ltd. provides wireless Internet services. Its products include wireless Direct Connect, connectivity, networks, voice, network security, datacentre and cloud, and consultancy and managed services. The company was founded by James McCall on November 25, 2003 and is headquartered in Manchester, the United Kingdom.

Roslin Cell Therapies Ltd. is a leading contract development and manufacturing services organization focused on advanced cell and gene therapies. The company was established in 2006 and is based in Edinburgh, UK. and has subsidiaries in the United States. Roslin Cell Therapies has a remarkable heritage in the field, having been among the first in the world to produce clinical-grade human pluripotent stem cells and advancing the first CRISPR edited stem cell-based therapy for a major disease to marketing authorization. The British company provides innovative process and analytical development, CGMP clinical and commercial manufacturing for a range of cell types, and CGMP iPSC cell line development, gene editing, and differentiation. With tailored CDMO solutions, Roslin Cell Therapies enables partners to efficiently progress from development to commercialization and deliver life-saving cell and gene therapies worldwide. Peter Alistair Coleman has been the CEO of the company since 2022.

Glycomine, Inc. engages in the development of therapeutics for diseases which have no treatment options. Its therapeutic approach is to combine replacement therapies such as substrates, enzymes, or proteins with intracellular delivery vehicles consisting of bio-nanomaterials or ligands that target the molecules to the cell interior of clinically relevant organs. It focuses on research of mannose-1-phosphate and Ngly1 enzyme replacement therapy, and observational study of GLY-000. The company was founded in 2014 by Agnes Rafalko and is headquartered in San Carlos, CA.

CiMaas BV develops cellular immunotherapy for cancer. Its products include cancer vaccine using the patient's own immune cells and the production of donor natural killer cells. The company was founded by Gerard M.J. Bos and Dilfred T.V. Germeraad and is headquartered in Maastricht, the Netherlands.

VectorY BV is a biotech company based in Amsterdam, Netherlands, that is dedicated to developing transformative medicines for people with neurodegenerative diseases such as ALS, Huntington's, and Parkinson's. VectorY's platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS, enabling long-lasting CNS treatment after a single administration using cutting-edge antibody, AAV, and manufacturing technologies. The Dutch company's unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing, and neuroscience drives the rapid development of much-needed disease-modifying therapies for neurodegenerative diseases. The company was founded by Sander J. van Deventer and Pavlina Konstantinova, with Sander J. van Deventer serving as the CEO since incorporation.

Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland.

Symeres provides molecule contract research, discovery, development and manufacturing services. The firm offers discovery chemistry, medicinal chemistry, early process research and GMP production services. The company is headquartered in Groningen, the Netherlands.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom.

MediService AG is a mail service pharmacy. The company is headquartered in Zuchwil, Switzerland.

PharmaCell BV manufactures cell therapy and regenerative medicine. The firm engages in human cell line development and manufacturing of bio pharmaceuticals. Its services include process research and development, project management, incoming logistics, incoming goods, manufacturing auto logous and allogeneic products, quality control, final formulation, release and outgoing logistics. The company was founded by René Lardenoije and Jan Thio in 2005 and is headquartered in Maastricht, the Netherlands.

Brabantse Ontwikkelings Maatschappij Holding BV (BOM) is an industrial and economic development agency headquarterd in Tilburg in the southern Netherlands. Established in 1983, BOM is funded and financed by the Dutch State and the Province of Noord-Brabant. The firm offers a range of services designed to create, develop, maintain and improve the industrial structure of the region through four core activities: venture capital, foreign investment, new business and industrial parks. In particular BOM manages the Technostartersfonds, also known as the TechnoStars funds, which are regional venture capital investment vehicles based in Eindhoven. The investors are primarily institutions and high-net worth private individuals.

Van Lanschot Kempen NV (Broker) (Van Lanschot Kempen-Broker) is the broker-dealer division of Van Lanschot Kempen NV (AMS: VLK), a financial institution headquartered in Amsterdam, Netherlands. The firm was founded in 1903 and formerly known as Kempen & Co. NV. Van Lanschot Kempen-Broker provides securities broking to institutional investors, companies, financial institutions, (semi) public institutions, foundations and high net-worth individual clients.

Sirius Medical BV engages in medical industry. The firm focuses on developing medical devices for oncological surgery. The company was founded by Hubert Martens and Bram Schermers and is headquartered in Eindhoven, the Netherlands.

NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands.

Rabo Private Equity (RPE) is the private equity arm of the Rabobank Group and is headquartered in Utrecht. RPE originated in 1972 following the merger of two separate Dutch cooperative banks, the Cooperatieve Centrale Raiffeisen-Boerenleenbank in Utrecht and the Cooperatieve Centrale Boerenleenbank in Eindhoven. The firm was formally established in 1998. RPE is based in Utrecht and operates through two separate entities, Rabo Participaties and Rabo Capital.

ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France.

River Biomedics B V I.O. is a Dutch biotech company that focuses on cardiac drug discovery. The company is based in Enschede, Netherlands. The company develops novel therapies for cardiac diseases by directly targeting the heart muscle using human predictive 3D in-vitro models and human induced pluripotent stem cell (hiPSC) technology. The company aims to address high unmet medical needs and provide detailed clinically relevant read-outs through high-throughput in-house screening platforms. River Biomedics values partnerships and strives for novelty by mimicking nature and connecting biology and engineering. The company was founded by Marcelo Ribeiro, Robert Passier, Lisanne Blauw, and the CEO is Nicky Cooper.

ApoGen Biotechnologies, Inc. operates as a biotechnology firm, which focuses on the development of therapeutics targeting drivers of cancer genomic mutation. The company was founded by John T. Santini, Jr., Reuben S. Harris, and Daniel A. Harki in 2014 and is headquartered in Seattle, WA.

Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands.

Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland.

FundaMental Pharma GmbH is a neuroscience company based in Heidelberg, Germany. The German company develops first-in-class small inhibitors for the treatment of a range of neurodegenerative diseases. The company's scientists have discovered an entirely new class of drugs that safely counteract glutamate excitotoxicity, a common cause of neurodegeneration. The company's current focus is on amyotrophic lateral sclerosis (ALS) and Huntington's disease, but the applicability of these molecules extends to a range of neurodegenerative disorders such as dementia and aging-related memory loss. FundaMental Pharma was founded in 2016 by Thomas Schulze, Hilmar Bading, and Daniela Mauceri, and Thomas Schulze has been the CEO since 2016.

Immunoprecise Antibodies (Europe) BV operates as a pharmaceutical company that specializes in antibiotics. Its services include antigen selection, antibody generation, antibody optimization, antibody production, antibody processing and assay development. The company was founded in 2004 and is headquartered in Oss, the Netherlands.